<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>72 patients were diagnosed as suffering from <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) according to the FAB classification: 16 patients with refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA), 11 patients with acquired idiopathic sideroblastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (AISA), 14 patients with refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with an excess of blast cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), 7 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/t) and 24 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The duration of the preleukaemic phase was between 2 and 189 months (median: 15 months); <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> showed a median phase of less than 12 months </plain></SENT>
<SENT sid="2" pm="."><plain>Transformation into <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (AL) occurred in 46 patients (64%) </plain></SENT>
<SENT sid="3" pm="."><plain>Of the clinical signs only <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> was a significant poor prognostic factor (p less than 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>Cytogenetic studies were made in 31 patients </plain></SENT>
<SENT sid="5" pm="."><plain>14 had clonal <z:mp ids='MP_0004024'>aneuploidy</z:mp>: these patients had a higher risk of AL, but not a significantly shorter preleukaemic phase (p greater than 0.1) </plain></SENT>
<SENT sid="6" pm="."><plain>Stem cell cultures (CFUc) were carried out in 31 patients </plain></SENT>
<SENT sid="7" pm="."><plain>Patients without colony growth or only cluster growth showed a high incidence (10/11 and 8/8) of transformation into AL; preleukaemic phases were significantly shorter than in patients with <z:mpath ids='MPATH_458'>normal</z:mpath> colony growth or cluster + colony growth in <z:hpo ids='HP_0000001'>all</z:hpo> FAB subgroups (p less than 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>The bone marrow blast cell count was indirectly proportional to the duration of the preleukaemic phase: <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, cytogenic aberrations and failure of in vitro colony growth are additional poor prognostic factors in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>